Abstracts Archive - Page 433 of 1683 - ATC Abstracts

2020 American Transplant Congress
Use of Direct Acting Antiviral Medications in Transplant Recipients Receiving Organs from Hepatitis C Viremic Donors
S. Bova¹, A. Cameron¹, C. Durand¹, J. Katzianer², M. LeGrand², L. Boyer¹, J. Glorioso³, L. P. Toman¹
¹The Johns Hopkins Hospital, Baltimore, MD, ²Johns Hopkins Home Care Group, Baltimore, MD, ³Thomas Jefferson Univeristy Hospital, Philadelphia, PA
*Purpose: The availability and high efficacy of direct acting antivirals (DAAs) to treat hepatitis C (HCV) is changing practice in solid organ transplant. A large…
2020 American Transplant Congress
Transplanting Livers from Hepatitis C Virus Positive Donors; Is it Worth the Risk?
J. W. Mensink¹, B. Van Hoek², B. Schaefer³, M. D. Van Rosmalen⁴, I. P. Alwayn⁵, A. E. Braat⁵
¹Leiden University Medical Center, Leiden, Netherlands, ²Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands, ³Dutch Transplant Foundation, Leiden, Netherlands, ⁴Eurotransplant International Foundation, Leiden, Netherlands, ⁵Transplant Surgery, Leiden University Medical Center, Leiden, Netherlands
*Purpose: Before the introduction of Direct-Acting Antivirals (DAAs), only selected organs from Hepatitis C virus (HCV) positive donors were successfully transplanted into HCV positive recipients.…
2020 American Transplant Congress
Epidemiology of EBV Infection and EBV Load Kinetics after Pediatric Living Donor Liver Transplantation
M. Yamada, A. Fukuda, M. Ogura, S. Shimizu, Y. Ishikawa, F. Kawano, H. Uchida, M. Takeda, Y. Yanagi, S. Sakamoto, M. Kasahara, K. Imadome
National Center for Child Health and Development, Tokyo, Japan
*Purpose: Epstein-Barr virus (EBV) is a ubiquitous virus that infects more than 90% of adult population worldwide. EBV infection after pediatric liver transplantation (LT) accounts…
2020 American Transplant Congress
Epstein-Barr Virus-Specific Cytotoxic T Lymphocyte Precursors (EBV-CTLp) after Tab-cel Correlates with Response & Survival in Rituximab Relapsing or Refractory Ebv⁺ Posttransplant Lymphoproliferative Disease (PTLD)
R. Shen¹, N. Guzman-Becerra¹, Y. Sun¹, F. Forozan¹, S. Prockop², E. Doubrovina², R. O'Reilly², X. Li¹, M. Hiremath³, L. Gamelin¹, W. Navarro¹, B. Aftab¹
¹Atara Biotherapeutics, Thousand Oaks, CA, ²Memorial Sloan Kettering Cancer Center, New York, NY, ³Atara Biotherapeutics, South San Francisco, CA
*Purpose: EBV+ PTLD is often a fatal disease. Tab-cel is an investigational off-the-shelf, allogeneic T-cell immunotherapy specific for EBV antigens. Functional in vivo expansion approximated…
2020 American Transplant Congress
Valganciclovir Prophylaxis is Not Associated with Polyomavirus Viremia after Renal Transplantation
D. Conti¹, D. Schuster¹, M. Garner¹, E. Maciera¹, S. Patel²
¹Albany Medical Center, Albany, NY, ²Surgery, Albany Medical Center, Albany, NY
*Purpose: Recent studies have implicated prophylactic valganciclovir (VGC) therapy after renal transplantation to be associated with an increased rate of BK polyomavirus viremia and nephropathy.…
2020 American Transplant Congress
Hematopoietic Cell Transplantation and Solid Organ Transplantation: Outcomes of Sequential Transplantation in the United States
M. Gupta¹, M. Levine², D. Porter², R. Brazauskas³, S. Bo-Subait⁴, R. Phelan³, M. Battiwalla⁵, D. Buchbinder⁶, B. Hamilton⁷, B. Shaw³, P. Abt²
¹University of Kentucky, Lexington, KY, ²University of Pennsylvania, Philadelphia, PA, ³Medical College of Wisconsin, Milwaukee, WI, ⁴CIBMTR, NMDP, Minneapolis, MN, ⁵Sarah Cannon Blood Cancer Network, Nashville, TN, ⁶Children's Hospital of Orange County, Orange, CA, ⁷Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
*Purpose: Survival after solid organ transplantation(SOT) and hematopoietic cell transplantation(HCT) has steadily risen. Despite these improvements, SOT recipients may develop conditions requiring HCT, and HCT…
2020 American Transplant Congress
Associations of Chronic Kidney Disease with Temperature, Ancestry and Employment
A. A. Connor, B. I. Shaw, K. V. Ravindra
Surgery, Duke University, Durham, NC
*Purpose: We sought to assess the suggested associations of chronic kidney disease (CKD) of unknown origin, also known as Mesoamerican Nephropathy, with temperature, ancestry and…
2020 American Transplant Congress
Male Native Hawaiians and Pacific Islanders are at Risk for Delayed Graft Function after Renal Transplantation
L. Lee¹, K. Bozhilov², L. L. Wong²
¹The Queen's Transplant Center, Honolulu, HI, ²Surgery, University of Hawaii - John A. Burns School of Medicine, Honolulu, HI
*Purpose: Native Hawaiians and Pacific Islanders (NHPI) have an increased risk of chronic kidney disease with disproportionately fewer patients receiving kidney transplants; this study aims…
2020 American Transplant Congress
Patient and Renal Outcomes of Post Transplant Lymphoproliferative Disorder Following Solid Organ Transplantations – A Single Center Experience
G. Katz-Greenberg¹, K. Mallari², U. Martinez-Outschoorn¹, M. P. MartinezCantarin¹
¹Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, PA, ²Thomas Jefferson University, Philadelphia, PA
*Purpose: Posttransplant lymphoproliferative disorder (PTLD) remains an unfortunate complication in patients following solid organ transplantation (SOT) and hematopoietic stem cells transplantations. The diagnosis of PTLD…
2020 American Transplant Congress
Osmotic Nephropathy from a Non-Sucrose Based IVIG
S. Reddy, L. Kodali
Nephrology, Mayo Clinic, Phoenix, AZ
*Purpose: We present a case of acute renal failure and hyperkalemia due to osmotic nephropathy from a non-sucrose based IVIG infusion therapy.*Methods: A 67-year-old man…